Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rituximab - Biogen Idec/Genentech

Drug Profile

Rituximab - Biogen Idec/Genentech

Alternative Names: IDEC-102; IDEC-C2B8; IDEC-C2B8-anti-CD20; MabThera; R 105; RG 105; Rituxan; Rituximab-EU; RO-452294

Latest Information Update: 25 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer AstraZeneca; Biogen; Biogen Idec; Cedars-Sinai Medical Center; Celgene Corporation; Chugai Pharmaceutical; Genentech; Hackensack University Medical Center; Hoosier Cancer Research Network; Janssen Research & Development; M. D. Anderson Cancer Center; Mayo Clinic; Nagoya University; Oregon Health & Science University; Roche; SCRI Development Innovations; Takeda Oncology; University of Gottingen; University of Texas M. D. Anderson Cancer Center; University of Tours; Zenyaku Kogyo
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies; Urologics
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Microscopic polyangiitis; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Pemphigus vulgaris; Granulomatosis with polyangiitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Granulomatosis with polyangiitis; Idiopathic thrombocytopenic purpura; Lymphoproliferative disorders; Microscopic polyangiitis; Nephrotic syndrome; Non-Hodgkin's lymphoma; Pemphigus vulgaris; Rheumatoid arthritis
  • Phase III Mantle-cell lymphoma; Transplant rejection
  • Phase II/III Neuromyelitis optica
  • Phase II B-cell lymphoma; Chronic inflammatory demyelinating polyradiculoneuropathy; Glomerulonephritis; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Renal transplant rejection
  • Phase I Multiple myeloma
  • No development reported Multiple sclerosis; Ocular inflammation; Primary biliary cirrhosis; Scleritis; Sjogren's syndrome; Ulcerative colitis
  • Discontinued Dermatomyositis; Graft-versus-host disease; Lupus nephritis; Systemic lupus erythematosus

Most Recent Events

  • 14 Oct 2019 Updated efficacy data from the phase III PEMPHIX trial in Pemphigus vulgaris released by Genentech
  • 11 Oct 2019 Phase-II clinical trials in Mantle-cell lymphoma (Combination therapy, First-line therapy) in USA (IV)
  • 04 Oct 2019 Rituximab - Biogen Idec/Genentech receives Orphan Drug status for Microscopic polyangiitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top